http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2023002784-A1
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d7347d71be8c8ab6824f7cbf71051693 |
classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-16043 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-87 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D491-048 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D491-052 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D498-18 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-86 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D498-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D491-052 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D491-048 |
filingDate | 2020-06-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6076c6627b8c2cc51a5d96008fb19dcc http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c58b9d0aae5c915cd1c583995fe5966b |
publicationDate | 2023-01-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | US-2023002784-A1 |
titleOfInvention | Compositions and methods for modifying eukaryotic cells |
abstract | Described herein are compositions and methods for modifying eukaryotic cells, for example, to express a transgene of interest and/or to produce an expanded population of cells ex vivo. Using the compositions and methods of the disclosure, a population of eukaryotic cells, such as a population of pluripotent cells (e.g., CD34+ hematopoietic stem or progenitor cells) may be transduced to express a gene of interest by contacting the cells with a viral vector, such as a lentiviral vector, and a poloxamer. Additionally, the compositions and methods described herein can be used to promote the proliferation or survival of a population of pluripotent cells (e.g., CD34+ hematopoietic stem or progenitor cells) ex vivo, for example, by contacting the cells with a poloxamer. Examples of poloxamers that may be used in conjunction with the compositions and methods of the disclosure are those having a molar mass in excess of 10,000 g/mol, as well as those having a molar mass of polyoxypropylene subunits greater than 2,000 g/mol and/or an ethylene oxide content of greater than 40% by mass. |
priorityDate | 2019-06-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 666.